rs114772660
Positions:
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_001372106.1(DNAH10):c.9199+9G>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0596 in 1,611,892 control chromosomes in the GnomAD database, including 3,238 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.073 ( 466 hom., cov: 32)
Exomes 𝑓: 0.058 ( 2772 hom. )
Consequence
DNAH10
NM_001372106.1 intron
NM_001372106.1 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.788
Genes affected
DNAH10 (HGNC:2941): (dynein axonemal heavy chain 10) Dyneins are microtubule-associated motor protein complexes composed of several heavy, light, and intermediate chains. The axonemal dyneins, found in cilia and flagella, are components of the outer and inner dynein arms attached to the peripheral microtubule doublets. DNAH10 is an inner arm dynein heavy chain (Maiti et al., 2000 [PubMed 11175280]).[supplied by OMIM, Mar 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.85).
BP6
Variant 12-123893445-G-A is Benign according to our data. Variant chr12-123893445-G-A is described in ClinVar as [Benign]. Clinvar id is 402619.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr12-123893445-G-A is described in Lovd as [Benign].
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.114 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
DNAH10 | NM_001372106.1 | c.9199+9G>A | intron_variant | ENST00000673944.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
DNAH10 | ENST00000673944.1 | c.9199+9G>A | intron_variant | NM_001372106.1 | P1 | ||||
DNAH10 | ENST00000409039.8 | c.9028+9G>A | intron_variant | 5 | |||||
DNAH10 | ENST00000638045.1 | c.8845+9G>A | intron_variant | 5 |
Frequencies
GnomAD3 genomes AF: 0.0726 AC: 11045AN: 152144Hom.: 466 Cov.: 32
GnomAD3 genomes
AF:
AC:
11045
AN:
152144
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0533 AC: 13134AN: 246320Hom.: 468 AF XY: 0.0531 AC XY: 7116AN XY: 133956
GnomAD3 exomes
AF:
AC:
13134
AN:
246320
Hom.:
AF XY:
AC XY:
7116
AN XY:
133956
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0583 AC: 85060AN: 1459630Hom.: 2772 Cov.: 32 AF XY: 0.0574 AC XY: 41700AN XY: 726106
GnomAD4 exome
AF:
AC:
85060
AN:
1459630
Hom.:
Cov.:
32
AF XY:
AC XY:
41700
AN XY:
726106
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0726 AC: 11058AN: 152262Hom.: 466 Cov.: 32 AF XY: 0.0703 AC XY: 5234AN XY: 74458
GnomAD4 genome
AF:
AC:
11058
AN:
152262
Hom.:
Cov.:
32
AF XY:
AC XY:
5234
AN XY:
74458
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
91
AN:
3478
ClinVar
Significance: Benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 29, 2016 | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Frequency - |
not provided Benign:1
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at